Brand Name :
Coreg, coreg CR
Synonyms :
Class :
Antihypertensive, Beta-blockers
Dosage Forms & Strengths
Capsule, extended release-10mg,20mg,40mg,80mg
Tablet-3.125mg,6.25mg,12.5mg,25mg
congestive Heart Failure (CHF)
Immediate release:
3.125
mg
orally
every 12 hrs
14
days
then increase every two weeks tolerated to 6.25mg,12.5mg, or 25 mg orally twice a day
Maximum recommended dose:
Mild to moderate heart failure:
<85 kg,25mg orally every 12 hours
>85kg,50mg orally twice daily
Severe heart failure:
25mg orally twice a day
Extended-release
10mg/day orally for 1-2 weeks, then increase 20mg/day,40mg/day, and 80mg/day orally
25 - 50
mg
Orally
twice a day
Tablet
left Ventricular Dysfunction Following Myocardial Infarction
Immediate release:
3.125 - 6.25
mg
Orally
every 12 hrs
3 - 10
days
Tablet
then increase to 12.5mg orally every 12 hours and then to 25mg orally every 12 hours
Extended-release
10mg/day orally for 3-10days, then increase to 80mg/day orally
Immediate release:
6.25
mg
orally
twice a day
14
days
Tablet
then increase to 12.5mg orally twice a day and then to 25 mg orally twice a day
Extended-release
20mg/day orally for 1-2 weeks, then increase to 40mg/day orally. Do not exceed 80mg/day orally
Dose Adjustments
Renal impairment: No dosage adjustment is necessary
Hepatic impairment: Not preferred in severe liver impairment
may increase the serum concentration of talazoparib
may decrease the antihypertensive effect when both drugs are combined
may decrease the antihypertensive effect when both drugs are combined
it enhances by affecting the hepatic enzyme CYP2C9 metabolism
it enhances by affecting the P-Glycoprotein (MDR1) efflux transporter
it enhances by affecting the hepatic enzyme CYP2C9 metabolism
May enhances the effects of the other by pharmacodynamic synergism
it enhances by affecting the P-Glycoprotein (MDR1) efflux transporter
It enhances the anti-hypertensive channel blocking when combined
it enhances by affecting the P-Glycoprotein (MDR1) efflux transporter
may increase the levels of each other by decreasing the metabolism
it enhances by affecting the P-Glycoprotein (MDR1) efflux transporter
May diminish the effects of carvedilol by pharmacodynamic antagonism
may decrease the bronchodilatory effect
may increase the level of effectiveness through P-glycoprotein MDR1 efflux transporter
may decrease the bronchodilatory effect
beta-Blockers may enhance the adverse/toxic effect of cholinergic agonists
beta-Blockers may enhance the adverse/toxic effect of cholinergic agonists
beta-Blockers may enhance the adverse/toxic effect of cholinergic agonists
beta-Blockers may enhance the adverse/toxic effect of cholinergic agonists
beta-Blockers may enhance the adverse/toxic effect of cholinergic agonists
May enhance the hypotensive effect of beta-Blockers
May enhance the hypotensive effect of beta-Blockers
May enhance the hypotensive effect of beta-Blockers
May enhance the hypotensive effect of beta-Blockers
May enhance the hypotensive effect of beta-Blockers
May enhance the hypotensive effect of beta-Blockers
May enhance the hypotensive effect of beta-Blockers
May enhance the hypotensive effect of beta-Blockers
May enhance the hypotensive effect of beta-Blockers
May enhance the hypotensive effect of beta-Blockers
beta-Blockers may enhance the hypoglycemic effect of sulfonylureas
beta-Blockers may enhance the hypoglycemic effect of sulfonylureas
beta-Blockers may enhance the hypoglycemic effect of sulfonylureas
beta-Blockers may enhance the hypoglycemic effect of sulfonylureas
beta-Blockers may enhance the hypoglycemic effect of sulfonylureas
it may enhance the serum potassium levels
It enhances the anti-hypertensive channel blocking when combined
May enhances the effects of the other by pharmacodynamic synergism
it enhances by affecting the hepatic enzyme CYP2C9 metabolism
it decreases by affecting the hepatic enzyme CYP2C9 metabolism
it enhances by affecting the hepatic enzyme CYP2C9 metabolism
it enhances the serum potassium levels
it decreases by affecting the hepatic enzyme CYP2C9 metabolism
May enhances the effects of the other by pharmacodynamic synergism
it may decrease the serum potassium levels
may increase the levels of each other by decreasing the metabolism
it enhances by affecting the hepatic enzyme CYP2C9 metabolism
it enhances the serum potassium levels
it may decrease the serum potassium levels
it enhances by affecting the P-Glycoprotein (MDR1) efflux transporter
it enhances by affecting the P-Glycoprotein (MDR1) efflux transporter
it may decrease the serum potassium levels
May enhances the effects of the other by pharmacodynamic synergism
it enhances by affecting the hepatic enzyme CYP2C9 metabolism
It enhances the anti-hypertensive channel blocking when combined
it enhances the serum potassium levels
May enhances the effects of the other by pharmacodynamic synergism
it enhances the serum potassium levels
May diminish the effects of propranolol by pharmacodynamic antagonism
it enhances by affecting the hepatic enzyme CYP2C9 metabolism
it enhances by affecting the hepatic enzyme CYP2C9 metabolism
It enhances the anti-hypertensive channel blocking when combined
it enhances the serum potassium levels
it decreases by affecting the hepatic enzyme CYP2C9 metabolism
May enhances the effects of the other by pharmacodynamic synergism
it enhances by affecting the P-Glycoprotein (MDR1) efflux transporter
May enhances the effects of the other by pharmacodynamic synergism
it enhances the serum potassium levels
it enhances by affecting the hepatic enzyme CYP2D6 metabolism
it enhances by affecting the hepatic enzyme CYP2D6 metabolism
may enhance the hypoglycemic effect of antidiabetic agents
may enhance the hypoglycemic effect of antidiabetic agents
may enhance the hypoglycemic effect of antidiabetic agents
may enhance the hypoglycemic effect of antidiabetic agents
may enhance the hypoglycemic effect of antidiabetic agents
may increase the hypotensive effect of beta-blockers
may increase the hypotensive effect of beta-blockers
may increase the hypotensive effect of beta-blockers
may increase the hypotensive effect of beta-blockers
may increase the hypotensive effect of beta-blockers
may increase the adverse effect of cholinergic agonists
may increase the adverse effect of cholinergic agonists
may increase the adverse effect of cholinergic agonists
may increase the adverse effect of cholinergic agonists
may increase the adverse effect of cholinergic agonists
may increase the effect of insulins
may increase the effect of insulins
may increase the effect of insulins
may increase the effect of insulins
may increase the effect of insulins
when both drugs are combined, there may be an increased risk or severity of adverse effects
acetylcholinesterase Inhibitors May enhance the bradycardic effect of beta-Blockers
acetylcholinesterase Inhibitors May enhance the bradycardic effect of beta-Blockers
acetylcholinesterase Inhibitors May enhance the bradycardic effect of beta-Blockers
acetylcholinesterase Inhibitors May enhance the bradycardic effect of beta-Blockers
acetylcholinesterase Inhibitors May enhance the bradycardic effect of beta-Blockers
amiodarone may enhance the bradycardic effect of beta-blockers
may increase the av-blocking effect of beta-blockers
may increase the av-blocking effect of beta-blockers
may increase the av-blocking effect of beta-blockers
may increase the av-blocking effect of beta-blockers
may increase the av-blocking effect of beta-blockers
it enhances by affecting the hepatic enzyme CYP2D6 metabolism
may increase the hypoglycaemic effect
may increase the hypoglycaemic effect
may increase the hypoglycaemic effect
may increase the hypoglycaemic effect
may increase the hypoglycaemic effect
it increases the effect of bradycardia of Beta-Blockers
Beta-Blockers increase the effect of hypoglycemia of insulins
Beta-Blockers increase the effect of hypoglycemia of insulins
Beta-Blockers increase the effect of hypoglycemia of insulins
Beta-Blockers increase the effect of hypoglycemia of insulins
Beta-Blockers increase the effect of hypoglycemia of insulins
may enhance the serum concentration of CYP2C9 inhibitors
may increase the toxic effect
may enhance the serum concentration of Beta-Blockers
may increase the effect of beta-blockers
may increase the effect of beta-blockers
may increase the effect of beta-blockers
may increase the effect of beta-blockers
may increase the effect of beta-blockers
may increase the effect of beta-blockers
may increase the effect of beta-blockers
may increase the effect of beta-blockers
may increase the effect of beta-blockers
may increase the effect of beta-blockers
may increase the effect of beta-blockers
may increase the effect of beta-blockers
may increase the effect of beta-blockers
may enhance the serum concentration when combined with mepivacaine
May enhances the effects of the other by pharmacodynamic synergism
May enhances the effects of the other by pharmacodynamic synergism
May enhances the effects of the other by pharmacodynamic synergism
May enhances the effects of the other by pharmacodynamic synergism
May enhances the effects of the other by pharmacodynamic synergism
May enhances the effects of the other by pharmacodynamic synergism
May enhances the effects of the other by pharmacodynamic synergism
May enhances the effects of the other by pharmacodynamic synergism
May diminish the effects of carvedilol by pharmacodynamic antagonism
Frequency defined:
>10%
Weight gain
Hypotension
Fatigue
Diarrhea
Dizziness
Hyperglycemia
1-10%
Nausea
Cough
Headache
Angina
Hypercholesterolemia
Vomiting
Dyspnea
Syncope
Rhinitis
Bradycardia
<10%
Insomnia
Palpitations
Impotence
Rales
Depression
Hepatotoxicity
Impotence
Raynaud phenomenon
Post-marketing report
Urinary incontinence
Interstitial pneumonitis
Aplastic anemia
Urticaria
Stevens-johnson syndrome
Be cautious with patients suffering from Chronic obstructive pulmonary disease, myocardial depression, hyperthyroidism, diabetes mellitus, pheochromocytoma, and myasthenia gravis.
Pregnancy consideration:
Insufficient data is available
US FDA pregnancy category: Not assigned
Lactation:
The drug is not excreted in the human breast milk
Pregnancy category:
Patient information leaflet
Generic Name: Carvedilol
Pronounced: [ KAR-ve-dil-ole]
Why do we use carvedilol?
Carvedilol treats hypertension (high blood pressure) and heart failure.